Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
about
sameAs
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraShiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeGenetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeAtypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literatureIs ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? NoThe development of atypical hemolytic uremic syndrome depends on complement C5Haemolytic uraemic syndrome.Induction by sphingomyelinase of shiga toxin receptor and shiga toxin 2 sensitivity in human microvascular endothelial cells.Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.HIV associated thrombotic microangiopathy.Hemolytic uremic syndrome: a case report from Africa.Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countriesComplement factor H deficiency in acute allograft glomerulopathy and post-transplant hemolytic uremic syndrome.Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.Systemic antithrombotic effects of ADAMTS13.Vascular lesions in nine Göttingen minipigs with thrombocytopenic purpura syndrome.The role of von Willebrand factor in hemorrhagic and thrombotic disorders.Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H-.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Hemolytic-uremic syndrome in a postpartum mare concurrent with encephalopathy in the neonatal foal.Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.High-dose immunoglobulin infusion for thrombotic thrombocytopenic purpura refractory to plasma exchange and steroid therapyShiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury.Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney.Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy.Targeting von Willebrand factor and platelet glycoprotein Ib receptor.Suspicious neuroimaging pattern of thrombotic microangiopathy.Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension.Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.Fulminant thrombotic microangiopathy in pediatrics: where diagnostic and therapeutic dilemmas meet.Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristicsShiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity.Endothelial cells and thrombotic microangiopathy.
P2860
Q24241470-BB7C185D-9CEB-4629-86CF-3ED4DB90966FQ24538771-AF68DB96-FC57-4139-9E14-BF23178F8737Q24543850-85D780B5-A4B9-4868-A628-1A4230E303F1Q24613907-10618AD7-246B-429C-8E5A-6E1147500D55Q24685473-FE773C68-BF11-484C-BC5F-1B4249F3D6BFQ26864297-8C35B909-A03D-4057-A291-475ED8288571Q28188198-59AA15EF-0147-41B4-9142-2E0794CBDFC8Q28300378-A6CBA3BA-A1EF-4817-8B1B-A6673095B410Q30244707-906F2326-6FBD-4AB8-BB68-2D886D3B0E73Q30310446-668074EF-D6B1-4F37-9002-42C02FDF6A7EQ31010561-DBE71A5B-9A64-438B-8371-D54209312B94Q33344468-F3845FE1-52DE-4175-BD80-2FE94426C47DQ33349440-0CD705C7-687C-4FB2-B8DA-49DA03AD04B6Q33349831-F4E5236D-53C0-4E3C-8320-E15E5AD51E09Q33359632-EAAE92EF-6F6C-4EC3-83F7-49C1F42C067DQ33364401-1CE7521B-CB9B-4244-90A5-D7E65DF505D4Q33365746-B4439494-9287-4E4A-A779-EC6DE540E88BQ33370540-577BA9C6-5B2B-4F67-8626-9186D292ACE9Q33371969-D4A53794-27DC-45F7-B207-6C37720F32FAQ33374578-BC9B24F9-9BAE-4CDA-8FBF-9E6F6E229E09Q33376471-18DA4A9B-5BA1-4AD5-8317-8D130DB3ECFAQ33377727-D6E50934-F86B-4553-BC0F-F5230853B980Q33378856-A9881AD6-0FC7-4DF6-9BB1-B574B282D745Q33380705-87015278-CA40-4074-A83F-DB22716655ECQ33381110-980B52BF-2E4C-4606-8BD6-A0FA45ACB547Q33382197-BC51F53E-93BF-41D8-9FB5-8647BB2C01C7Q33382787-1535EE17-532C-42AD-99A2-1BD282F563EDQ33384039-6A39A6DE-D943-4072-A899-FD60F663CC5BQ33386213-BBBC7D74-53B3-45F1-8F1C-8A1E41FA10CBQ33389014-A07C6D98-5C8C-4537-BD9C-3428258AE07BQ33392316-986003D9-F72A-4307-94AB-93D0AEE15078Q33392975-471FBBD8-835A-44DE-97F3-020BC1CF9F27Q33393979-0745C894-A684-4139-9853-7FB9E28FE139Q33395253-56EFF127-A4B9-4F8F-8B50-AA7F9779DE70Q33395953-F539FF0A-FAE8-4E0D-A6CA-761E0D04C2F7Q33398967-CEFD7F8A-5C73-4E25-9BCE-E695A165E801Q33400197-128DE2E9-CCF1-43FB-85AD-7D5E63EF9226Q33400211-751A78CA-287D-4A5A-9142-C99188B63878Q33400603-1DE9DEB9-106A-41B8-AE39-09066B70DC01Q33401369-3B7F0FF1-C065-4E01-8A33-394E0E6BCA16
P2860
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@ast
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@en
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@nl
type
label
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@ast
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@en
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@nl
prefLabel
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@ast
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@en
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@nl
P3181
P1433
P1476
Thrombotic microangiopathy, he ...... botic thrombocytopenic purpura
@en
P2093
P304
P3181
P356
10.1046/J.1523-1755.2001.060003831.X
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1013940552